FindTrial
Sign In

CYNK-001

BIOLOGICAL3 trials

Sponsors

Celularity Incorporated

Conditions

ARDSAlkylating AgentsAnalgesicsAnalgesics, Non-NarcoticAnalgesics, Non-narcoticAnti-infective AgentsAntimetabolites, AntineoplasticAntineoplastic Agents

Phase 1

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
NCT04309084
Celularity IncorporatedAnalgesics, Analgesics, Non-Narcotic, Antineoplastic Agents +17
Start: 2020-05-12End: 2023-04-30Target: 29Updated: 2023-02-16
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
TerminatedNCT04310592
Celularity IncorporatedAlkylating Agents, Analgesics, Analgesics, Non-narcotic +17
Start: 2020-03-12End: 2023-04-28Updated: 2024-12-12
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
TerminatedNCT04365101
Celularity IncorporatedAnalgesics, Anti-infective Agents, Antimetabolites, Antineoplastic +17
Start: 2020-09-02End: 2023-02-15Updated: 2026-06-26

Related Papers

The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19.
2024-12-271 citations
Results of Cynk-001-AML-001: A Phase I Multi-Dose Study Evaluating the Safety, Tolerability, and Persistence of Cynk-001 in Adults with De Novo or Secondary Acute Myeloid Leukemia in Morphologic Complete Remission with Minimal Residual Disease or Relapsed/Refractory AML
Blood2023-11-026 citations
Conditioning Impacts on Regulatory T-Cells (Tregs) in the Microenvironment of AML: Observations from the Phase 1 Cynk-001-AML-001 Trial
Blood2023-11-02
Safety and feasibility study of ex vivo expanded allogeneic-NK cells infusion in patients with acute pneumonia caused by COVID-19
Pilot and Feasibility Studies2023-08-0416 citations
Abstract CT201: Early report of a phase I/II study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) for the treatment of adults with COVID-19 (NCT04365101)
Cancer Research2021-07-015 citations